U.S. study finds Ozempic, Wegovy linked to increased risk of rare form of blindness

The study showed people with diabetes were more than four times more likely to be diagnosed with non-arteritic anterior ischemic optic neuropathy (NAION) if they were taking a prescription semaglutide and those who were overweight or obese were more than seven times more likely to experience the condition if they were taking the medication. The risk was found to be greatest within the first year of receiving a prescription for semaglutide. Experts agree the potential risk of NAION shouldn’t deter the use of semaglutide medications to treat diabetes or obesity.